Who are HPV-16/18 L1/AS04's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Licensed seasonal influenza vaccine, SARS-CoV-2 rS antigen/Matrix-M Adjuvant.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hpv-16-18-l1-as04.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

HPV-16/18 L1/AS04 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HPV-16/18 L1/AS04 (HPV-16/18 L1/AS04) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant protein vaccine with adjuvant. Area: Oncology / Immunology.

phase 3 Recombinant protein vaccine with adjuvant HPV-16 L1 and HPV-18 L1 capsid proteins Oncology / Immunology Biologic Live · refreshed every 30 min

Target snapshot

HPV-16/18 L1/AS04 (HPV-16/18 L1/AS04) — GlaxoSmithKline. This vaccine stimulates the immune system to produce antibodies and cellular immunity against HPV-16 and HPV-18 L1 capsid proteins, preventing infection and cervical cancer development.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
HPV-16/18 L1/AS04 TARGET	HPV-16/18 L1/AS04	GlaxoSmithKline	phase 3	Recombinant protein vaccine with adjuvant	HPV-16 L1 and HPV-18 L1 capsid proteins
Licensed seasonal influenza vaccine	Licensed seasonal influenza vaccine	Novavax	marketed	Recombinant protein vaccine with adjuvant	Influenza hemagglutinin (HA) protein
SARS-CoV-2 rS antigen/Matrix-M Adjuvant	SARS-CoV-2 rS antigen/Matrix-M Adjuvant	Novavax	phase 3	Recombinant protein vaccine with adjuvant	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant protein vaccine with adjuvant class)

Novavax · 2 drugs in this class
GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HPV-16/18 L1/AS04 — Competitive Intelligence Brief. https://druglandscape.com/ci/hpv-16-18-l1-as04. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab